MREO241220C3000
- 0.73
- -0.17-18.89%
Mereo BioPharma Newsroom
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Mereo BioPharma Group Analyst Ratings
Buy Rating Affirmed for Mereo Biopharma on Strong Financials and Promising Pipeline Progress
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Mereo Biopharma on Strong Clinical and Financial Prospects
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Mereo BioPharma Group Analyst Ratings
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Mereo BioPharma Group Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Mereo BioPharma Group Analyst Ratings
Leerink Partners Maintains Outperform on Mereo BioPharma Group, Raises Price Target to $8
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Mereo BioPharma Group Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)